• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tarsus Pharmaceuticals Inc (NQ: TARS )

    29.03 +2.86 (+10.93%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,137,277
    Open 26.01
    Bid (Size) 29.03 (2)
    Ask (Size) 29.70 (2)
    Prev. Close 26.17
    Today's Range 25.82 - 29.50
    52wk Range 12.57 - 42.50
    Shares Outstanding 20,574,104
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
    TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +44.00%
    +44.00%
    1 Month
    +34.77%
    +34.77%
    3 Month
    -12.06%
    -12.06%
    6 Month
    -18.84%
    -18.84%
    1 Year
    +74.67%
    +74.67%

    More News

    Read More
    Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Analyst Ratings For Tarsus Pharmaceuticals
    Via Benzinga
    Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) is a Stock Spotlight on 4/15
    Via Investor Brand Network
    Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Tarsus to Participate in Upcoming Investor Conferences
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Simple Ways To Stay With Trends: The Week In Charts
    Via Talk Markets
    Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus to Participate at Upcoming Investor Conferences
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus Announces Pricing of $100.0 Million Public Offering
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus Announces Proposed $100.0 Million Public Offering
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.